BioNTech SE Sponsored ADR (BNTX - Free Report) closed at $124.57 in the latest trading session, marking a +1.63% move from the prior day. This change outpaced the S&P 500's 1.44% gain on the day. At the same time, the Dow added 1.26%, and the tech-heavy Nasdaq gained 5.21%.
Heading into today, shares of the company had lost 4.23% over the past month, lagging the Medical sector's gain of 2.17% and the S&P 500's gain of 2.28% in that time.
Investors will be hoping for strength from BioNTech SE Sponsored ADR as it approaches its next earnings release. In that report, analysts expect BioNTech SE Sponsored ADR to post earnings of $0.65 per share. This would mark a year-over-year decline of 95.93%. Meanwhile, our latest consensus estimate is calling for revenue of $1.91 billion, down 73.27% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.69 per share and revenue of $6.08 billion, which would represent changes of -85.7% and -66.96%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BioNTech SE Sponsored ADR. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 53.82% lower. BioNTech SE Sponsored ADR currently has a Zacks Rank of #4 (Sell).
Looking at its valuation, BioNTech SE Sponsored ADR is holding a Forward P/E ratio of 21.56. For comparison, its industry has an average Forward P/E of 20.56, which means BioNTech SE Sponsored ADR is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 86, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks<<
BioNTech SE Sponsored ADR (BNTX - Free Report) closed at $124.57 in the latest trading session, marking a +1.63% move from the prior day. This change outpaced the S&P 500's 1.44% gain on the day. At the same time, the Dow added 1.26%, and the tech-heavy Nasdaq gained 5.21%.
Heading into today, shares of the company had lost 4.23% over the past month, lagging the Medical sector's gain of 2.17% and the S&P 500's gain of 2.28% in that time.
Investors will be hoping for strength from BioNTech SE Sponsored ADR as it approaches its next earnings release. In that report, analysts expect BioNTech SE Sponsored ADR to post earnings of $0.65 per share. This would mark a year-over-year decline of 95.93%. Meanwhile, our latest consensus estimate is calling for revenue of $1.91 billion, down 73.27% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.69 per share and revenue of $6.08 billion, which would represent changes of -85.7% and -66.96%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BioNTech SE Sponsored ADR. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 53.82% lower. BioNTech SE Sponsored ADR currently has a Zacks Rank of #4 (Sell).
Looking at its valuation, BioNTech SE Sponsored ADR is holding a Forward P/E ratio of 21.56. For comparison, its industry has an average Forward P/E of 20.56, which means BioNTech SE Sponsored ADR is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 86, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks<<
Get the latest research report on BNTX - FREE